Will this news give the AstraZeneca share price a shot in the arm?

US FDA has approved Lynparza for pancreatic cancer treatment. I explore whether this makes AstraZeneca a buy for 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2019 was filled with challenges: various geopolitical events tested the global economy as well as financial markets. But AstraZeneca (LSE: AZN) managed to end the year on a positive and encouraging note. Its drug Lynparza (olaparib) – which it has co-developed and co-commercialised with Merck (known as MSD outside of the US and Canada) – received regulatory approval for the treatment of pancreatic cancer.

With this approval, the drug – which was already in use for treating multiple forms of cancer – creates a niche in cancer treatment. The approval was provided by the US Food and Drug Administration.

Lynparza is classified as a poly ADP ribose polymerase (PARP) inhibitor. It helps in saving cells’ DNA repair mechanism, which stops cancer cells from duplicating. In this manner, it stops the sustenance of tumors. The latest approval will allow it to be used by pancreatic cancer patients on whom chemotherapy had been ineffective even after 16 weeks of treatment.

A brief background

AstraZeneca and Merck had announced a collaboration on oncology in July 2017. At the time, Lynparza was used for ovarian cancer treatment and its pipeline had included breast, prostrate and pancreatic cancers, among others.

On the collaboration, Chief Executive Officer of AstraZeneca Pascal Soriot had said “By bringing together the expertise of two leading oncology innovators, we will accelerate Lynparza’s potential to become the preferred backbone of many immuno-oncology combination therapies as the world’s first and leading PARP inhibitor.”

As part of the collaboration agreement, Merck had decided to pay AstraZeneca up to $8.5 billion in total consideration, including $1.6 billion upfront, $750 million for certain license options and up to $6.15 billion depending upon successful achievement of future regulatory and sales milestones.

What does this approval mean for investors?

AstraZeneca stock has had an excellent 2019. Until December 30, its share price had increased by 31.5% for the year. Its profits have been great as well, powered by new medicine sales which surged by 62% to $2.7 billion in Q3.

Soriot’s outlined objectives for the collaboration with Merck, as stated above, indicate to me that the partnership has been able to achieve its chief aims. Its pipeline is continuing to be realised, which is a testimony to its drug quality. My takeaway from this is that its medicine sales, especially from the oncology vertical, would continue to be strong.

Political uncertainty has subsided in the UK but some headwinds still remain. Globally, economic challenges await the world in 2020. I believe that these factors could push investors towards defensive purchases like stocks of pharmaceutical companies in the first half of the year, which would benefit AstraZeneca.

Its P/E ratio, hovering at the 25 mark and over, is on the higher side, but its continued success with oncology medication indicates further momentum for its share price. Investors are also looking forward to the results from its POSEIDON trial. The initial results of the trial, being conducted for drugs treating lung cancer, were quite encouraging.

The new approval for Lynparza not only provides more treatment options for cancer patients – in my view, it may be beckoning a buying opportunity for investors as well.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Divyansh Awasthi has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »